<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000162.pub2" GROUP_ID="STROKE" ID="658399073016083430" MERGED_FROM="" MODIFIED="2008-09-17 15:50:27 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0002" REVMAN_SUB_VERSION="5.0.15" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2008-09-17 15:50:27 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke</TITLE>
<CONTACT MODIFIED="2008-09-17 15:50:27 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="7166" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Philip</FIRST_NAME><MIDDLE_INITIALS>MW</MIDDLE_INITIALS><LAST_NAME>Bath</LAST_NAME><SUFFIX>FRCP</SUFFIX><POSITION>Stroke Association Professor of Stroke Medicine</POSITION><EMAIL_1>philip.bath@nottingham.ac.uk</EMAIL_1><MOBILE_PHONE>07798 670726</MOBILE_PHONE><ADDRESS><DEPARTMENT>Division of Stroke Medicine</DEPARTMENT><ORGANISATION>University of Nottingham</ORGANISATION><ADDRESS_1>South Block D Floor</ADDRESS_1><ADDRESS_2>Queens Medical Centre</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 823 1768</PHONE_1><FAX_1>+44 115 823 1767</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-09-17 15:50:27 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="7166" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Philip</FIRST_NAME><MIDDLE_INITIALS>MW</MIDDLE_INITIALS><LAST_NAME>Bath</LAST_NAME><SUFFIX>FRCP</SUFFIX><POSITION>Stroke Association Professor of Stroke Medicine</POSITION><EMAIL_1>philip.bath@nottingham.ac.uk</EMAIL_1><MOBILE_PHONE>07798 670726</MOBILE_PHONE><ADDRESS><DEPARTMENT>Division of Stroke Medicine</DEPARTMENT><ORGANISATION>University of Nottingham</ORGANISATION><ADDRESS_1>South Block D Floor</ADDRESS_1><ADDRESS_2>Queens Medical Centre</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 823 1768</PHONE_1><FAX_1>+44 115 823 1767</FAX_1></ADDRESS></PERSON><PERSON ID="16321" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Fiona</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Bath-Hextall</LAST_NAME><POSITION>Associate Professor, </POSITION><EMAIL_1>fiona.bath-hextall@nottingham.ac.uk</EMAIL_1><MOBILE_PHONE>07816925547</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Nursing, Faculty of Medicine and Health Science</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Room D83, Medical school</ADDRESS_1><ADDRESS_2>Queens medical centre</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2UH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 115 8230884</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-09-17 14:11:11 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="16" MONTH="3" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="11" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2008-09-17 14:12:40 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="17" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-17 14:44:56 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-17 14:44:56 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="16" MONTH="3" YEAR="2004"/>
<DESCRIPTION>
<P>November 2003<BR/>(1) Further searches<BR/>(2) Addition of more excluded trials<BR/>
<BR/>NOTE: This review covers an area where, as far as we know, no active research is taking place. It will be updated if relevant information becomes available, e.g. on completion of an appropriate study.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>NHS South Thames Region Research and Development Programme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Wolfson Foundation</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>The Stroke Association</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-17 14:46:40 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-09-17 14:13:35 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-09-17 14:13:35 +0100" MODIFIED_BY="Hazel Fraser">Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-17 14:13:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>Methylxanthines can enlarge brain blood vessels but are of no apparent benefit in the early treatment of strokes caused by blood clots. Most strokes are caused by a blood clot which then reduces blood flow in the affected part of the brain. Without an adequate blood supply, the brain quickly suffers damage which is often permanent. Drugs which can improve brain blood flow might reduce damage and improve outcome after stroke. Methylxanthines can alter brain blood flow but we do not know if they improve patient recovery. We found five small trials which do not show any clear benefit. The use of methylxanthines in acute stroke cannot be recommended at present.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-09-17 14:15:01 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND MODIFIED="2008-09-17 14:12:55 +0100" MODIFIED_BY="Hazel Fraser">
<P>Methylxanthine derivatives are vasodilators. They also inhibit platelet aggregation and thromboxane A2 synthesis, decrease the release of free radicals and may be neuroprotective. This review covers an area where no active research is taking place. It will be updated if relevant information becomes available, e.g. on completion of an appropriate study.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effect of intravenous or oral methylxanthines (pentoxifylline, propentofylline, or pentifylline) in patients with acute ischaemic stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Stroke Group trials register (last searched November 2003). For the first version, we also searched EMBASE (1980 to 1999), MEDLINE (1966 to 1999), Science Citation Index (1981 to 1999) and the Ottawa Stroke Trials Registry. We also contacted the manufacturers of methylxanthines and the principal investigators of the identified trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials comparing pentoxifylline, propentofylline or pentifylline with placebo or control in patients with definite or presumed acute ischaemic stroke. Trials were included if treatment was started within one week of stroke onset.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-09-17 14:15:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>Two review authors independently applied the inclusion criteria. Trial quality was assessed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Five trials were included. Four trials tested pentoxifylline in 763 people, and one tested propentofylline in 30 people. No trials of pentifylline were found. The odds of early death (within four weeks) was non-significantly reduced in patients given a methylxanthine drug as compared with those given placebo (odds ratio (OR) 0.64, 95% confidence interval (CI) 0.41 to 1.02). This non-significant trend to less deaths was due mainly to one pentoxifylline trial that found a highly significant reduction in early deaths. Two trials reported early death or disability and found a non-significant reduction (OR 0.49, 95% CI 0.20 to 1.20). There was no significant difference in late death (beyond four weeks), as reported in the propentofylline trial involving 30 patients, although the confidence interval was wide (OR 0.70, 95% CI 0.13 to 3.68). Data for neurological impairment and disability were not in a form suitable for analysis. Data on quality of life, stroke recurrence, thromboembolism and bleeding were not reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is not enough evidence to assess adequately the effectiveness and safety of methylxanthines after acute ischaemic stroke.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-17 14:46:40 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND>
<P>Acute stroke is the third most common cause of death in the Western world and the most common cause of long-term adult disability. Although there are no proven safe acute treatments for ischaemic stroke, potential therapeutic strategies include antiplatelet, antileucocyte, vasodilator or neuroprotective agents (<LINK REF="REF-Bath-1995" TYPE="REFERENCE">Bath 1995</LINK>).</P>
<P>An alternative approach involves the use of agents which combine these properties such as the methylxanthine derivatives, pentoxifylline (oxpentifylline), pentifylline and propentofylline. These agents have mixed actions; they (i) inhibit cAMP- and cGMP-phosphodiesterases (thereby increasing the intracellular concentrations of these calcium-regulating cyclic nucleotides), (ii) block the adenosine transporter thereby preventing adenosine uptake and increasing adenosine levels (<LINK REF="REF-Andine-1990" TYPE="REFERENCE">Andine 1990</LINK>), and (iii) block phospholipase (<LINK REF="REF-Ward-1987" TYPE="REFERENCE">Ward 1987</LINK>). Additionally, propentofylline has been shown to increase brain GABA concentrations (<LINK REF="REF-Vukadinovic-1986" TYPE="REFERENCE">Vukadinovic 1986</LINK>) and reduce glutamate release under ischaemic conditions (<LINK REF="REF-Andine-1990" TYPE="REFERENCE">Andine 1990</LINK>; <LINK REF="REF-Miyashita-1992" TYPE="REFERENCE">Miyashita 1992</LINK>). As a result of the above, methylxanthine derivatives are vasodilators, inhibit platelet aggregation and thromboxane A2 synthesis, inhibit phagocyte function (e.g. decrease the release of free radicals), increase prostacyclin synthesis from endoperoxides, reduce blood viscosity through increasing erythrocyte flexibility, decreasing erythrocyte aggregation and reducing plasma fibrinogen concentration (<LINK REF="REF-Ott-1983" TYPE="REFERENCE">Ott 1983</LINK>), and may be neuroprotective (<LINK REF="REF-Ward-1987" TYPE="REFERENCE">Ward 1987</LINK>) as adenosine inhibits glutamate release. Pentoxifylline has been shown to increase cerebral blood flow in patients with acute stroke (<LINK REF="STD-Hartmann-1986" TYPE="STUDY">Hartmann 1986</LINK>). Ischaemic stroke is characterised by thrombosis, red cell, platelet and leucocyte aggregation, leucocyte infiltration, free radical generation, excess glutamate release, and reduced GABA release. Hence, pentoxifylline and analogues are candidate treatments for acute ischaemic stroke.</P>
<P>Pre-clinical studies in gerbils and cats suggest that pentoxifylline and propentofylline reduce neural damage following ischaemia (<LINK REF="REF-Bluhm-1985" TYPE="REFERENCE">Bluhm 1985</LINK>; <LINK REF="REF-DeLeo-1988" TYPE="REFERENCE">DeLeo 1988</LINK>; <LINK REF="REF-Ganser-1974" TYPE="REFERENCE">Ganser 1974</LINK>; <LINK REF="REF-Hartmann-1977" TYPE="REFERENCE">Hartmann 1977</LINK>). Similarly, uncontrolled open trials have suggested that pentoxifylline may improve stroke outcome (<LINK REF="REF-Schneider-1983" TYPE="REFERENCE">Schneider 1983</LINK>). As a result, a number of randomised placebo-controlled trials of pentoxifylline and propentofylline in cerebral ischaemia have been performed and are the subject of this Cochrane systematic review.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-09-17 14:45:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>To determine whether oral or intravenous pentoxifylline (oxpentifylline), propentofylline and pentifylline (1) are safe to administer in acute ischaemic stroke, (2) reduce early and late case fatality, (3) improve functional dependency at late follow up after stroke, and (4) improve quality of life after stroke.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-17 14:46:40 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2008-09-17 14:46:40 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES>
<P>Randomised unconfounded placebo-controlled or open trials of pentoxifylline, propentofylline or pentifylline administered within seven days of the onset of ischaemic stroke. Trials where the above agents were compared with other potentially active therapies and those in chronic cerebrovascular disease or vascular dementia were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with stroke of any age and either gender who were not known to have had a primary intracerebral haemorrhage, i.e. with definite or presumed acute ischaemic stroke.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>All randomised placebo-controlled comparisons of oral or intravenous pentoxifylline, propentofylline or pentifylline where the drug was started within seven days of stroke onset.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-09-17 14:46:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>The primary outcome measure was early all-cause death (deaths within four weeks of enrolment). Secondary outcomes included: deaths from any cause during scheduled follow up if longer than four weeks; the number of patients who died or deteriorated neurologically within the first four weeks; the number of cases who died or were disabled at the end of scheduled follow up if longer than four weeks; the number of cases suffering a recurrent stroke during the treatment period; the number of cases of venous thromboembolism during the treatment period; drug safety during the treatment period; and late quality of life at the end of follow up.</P>
<P>Deterioration was defined as a reduction in neurological impairment score; disability was defined as dependency in activities in daily living; drug safety was defined as major systemic or intracranial bleeding; quality of life was measured by a recognised scale.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-17 14:17:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>Relevant trials were identified in the Cochrane Stroke Group trials register, which was last searched by the Review Group Co-ordinator in November 2003.</P>
<P>For the first version of this review, we also searched EMBASE (1980 to 1999), MEDLINE (1966 to 1999), Science Citation Index (1981 to 1999), and the Ottawa Stroke Trials Registry. Electronic search terms included: (stroke or cerebr*) and (pentoxifylline or oxpentifylline or propentofylline or pentifylline or Trental or HWA 285).</P>
<P>In an effort to identify unpublished trials we contacted the manufacturers of pentoxifylline, propentofylline and pentifylline: Hoechst, Hoechst Roussel Pharmaceuticals. Additional information was sought from the principal investigators of the identified trials, and reviews of xanthine derivatives in cerebrovascular disease (<LINK REF="REF-Martindale-1993" TYPE="REFERENCE">Martindale 1993</LINK>; <LINK REF="REF-Ward-1987" TYPE="REFERENCE">Ward 1987</LINK>).</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-09-17 14:18:19 +0100" MODIFIED_BY="Hazel Fraser">
<P>Two of us (PB, FB) independently selected trials for inclusion in the review and sought additional information from the principal investigators of these trials. Information on the methods of randomisation, concealment of allocation, blinding, exclusion of cerebral haemorrhage, analysis (intention to treat versus efficacy analysis), drug dose, route and timing, the numbers of deaths, deterioration, and functional disability, were recorded.</P>
<P>We assessed the methodological quality of trials using standard Cochrane criteria. We analysed by intention to treat, tested for heterogeneity, and calculated a weighted estimate of the typical treatment effect across trials (odds ratio) using the Peto fixed-effect model in the Cochrane Review Manager software, RevMan 4.2. The effects of pentoxifylline and propentofylline were analysed separately and together.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-17 14:21:16 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2008-09-17 14:19:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>Five trials met our inclusion criteria (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). Three of the trials have been published as full reports (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>; <LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>; <LINK REF="STD-Huber-1993" TYPE="STUDY">Huber 1993</LINK>) and one in abstract form (<LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>). Two other trials, sponsored by Hoechst, have been undertaken; one has been presented as an internal company report (<LINK REF="STD-Hoechst-1986" TYPE="STUDY">Hoechst 1986</LINK>) whilst information on the other, which appears to have involved oral pentoxifylline, is awaited from the company (<LINK REF="STD-Hoechst-1985" TYPE="STUDY">Hoechst 1985</LINK>). Four of the trials used pentoxifylline (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>; <LINK REF="STD-Hoechst-1986" TYPE="STUDY">Hoechst 1986</LINK>; <LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>; <LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>); the fifth trial used propentofylline (<LINK REF="STD-Huber-1993" TYPE="STUDY">Huber 1993</LINK>), an analogue of pentoxifylline. No trials of pentifylline in acute stroke appear to have been undertaken. Sixteen trials were excluded as detailed in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>Pentoxifylline and propentofylline were administered by continuous intravenous infusions lasting three days (<LINK REF="STD-Hoechst-1986" TYPE="STUDY">Hoechst 1986</LINK>; <LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>; <LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>), five days (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>), or seven days (<LINK REF="STD-Huber-1993" TYPE="STUDY">Huber 1993</LINK>).Two trials involved additional potentially active treatments administered to both treatment and control groups; aspirin was administered with pentoxifylline or placebo in one trial (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>) whilst glycerine was given with pentoxifylline or placebo in another (<LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>). The Hoechst, Hsu, and Wong trials followed pentoxifylline infusions with oral pentoxifylline (<LINK REF="STD-Hoechst-1986" TYPE="STUDY">Hoechst 1986</LINK>; <LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>; <LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>).</P>
<P>None of the trials reported quality of life, bleeding episodes or venous thromboembolism; the trials of Hsu and Huber gave disability results (Barthel Index) at two weeks but these were not dichotomised and cannot be analysed without the original patient data (<LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>; <LINK REF="STD-Huber-1993" TYPE="STUDY">Huber 1993</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-09-17 14:20:51 +0100" MODIFIED_BY="Hazel Fraser">
<P>The methods used in the five trials are summarised in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Allocation was adequately concealed in four trials. Four trials were double-blind (i.e. patients and doctors were blinded to treatment) placebo-controlled, truly randomised, and analysed by the intention-to-treat method; the trial of Wong was single-blind (patients only blinded to treatment) and analysed by intention to treat (<LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>). Two trials were multicentre studies involving 297 (<LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>) and 266 (<LINK REF="STD-Hoechst-1986" TYPE="STUDY">Hoechst 1986</LINK>) patients respectively; the other three were single centre and involved 90 (<LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>), 110 (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>) and 30 (<LINK REF="STD-Huber-1993" TYPE="STUDY">Huber 1993</LINK>) patients respectively. All trials used CT scans to exclude primary intracerebral haemorrhage. Enrolment varied from within 12 hours (<LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>) to within 48 hours (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>). The late enrolment of patients in the Chan trial (36 to 48 hours) was due to delayed hospital admission of stroke patients, especially those with lacunar stroke (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>). One trial was stratified into lacunar and cortical infarction (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>). In contrast, the Hsu trial was stratified by vascular territory (carotid versus vertebrobasilar) (<LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-09-17 14:21:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>The total number of participants in the five analysed trials numbered 793. The average age of patients in the trials was 68 years and almost two-thirds were male. There was some evidence of statistical heterogeneity in the early case fatality analysis (chi squared 8.39, df = 4, P = 0.08), mainly due to the findings of one trial (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>) (see below).</P>
<P>Early case fatality (within four weeks) was assessed in four trials of pentoxifylline (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>; <LINK REF="STD-Hoechst-1986" TYPE="STUDY">Hoechst 1986</LINK>; <LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>; <LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>); a non-significant reduction in the odds of early death of 35% (95% confidence interval (CI), 59% reduction to 4% excess) was observed. It is noteworthy that this result is almost completely dependent on the statistically significant mortality difference observed between the pentoxifylline and placebo groups in the trial of Chan which found a large reduction in the odds of early death of 90% (95% CI, 98% reduction to 56% reduction) (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>). If the Chan trial is removed from this analysis, the reduction in the odds of early case fatality reduces to 21% (95% CI, 58% reduction to 50% excess). When combining both pentoxifylline and propentofylline, a non-significant 36% reduction (95% CI, 59% reduction to 2% excess) in the odds of early death was observed. Two trials assessed the combined outcome of early death or deterioration (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>; <LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>) and found a non-significant odds reduction of 51% (95% CI, 80% reduction to 20% excess).</P>
<P>Only one trial studied late case fatality (less than one year); Huber and colleagues reported a non-significant reduction in odds of 30% (95% CI, 87% reduction to 268% excess) (<LINK REF="STD-Huber-1993" TYPE="STUDY">Huber 1993</LINK>). Hsu and Huber reported Barthel Indices at two weeks (<LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>; <LINK REF="STD-Huber-1993" TYPE="STUDY">Huber 1993</LINK>); however, in the absence of the original data it is not possible to further analyse this data. None of the trials reported data relating to late disability, quality of life, stroke recurrence, or the incidence of venous thromboembolism or major bleeding.</P>
<P>These analyses are dependent on our intention to analyse early deaths as those that occurred within 28 days of stroke onset (as specified in the original protocol). However, Hsu and colleagues reported three extra deaths in the pentoxifylline group that occurred between days 29 and 35 although they had intended to report deaths up to four weeks (as detailed in their methods section); we have ignored these extra deaths since they are outside our four week cut-off whilst Hsu et al did not give details on their deaths for their control group beyond 28 days (<LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>).</P>
<P>Side-effects were reported in two trials. Both the Hsu and Hoechst trials found an excess of nausea and vomiting in those patients receiving pentoxifylline (<LINK REF="STD-Hoechst-1986" TYPE="STUDY">Hoechst 1986</LINK>; <LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>), e.g. for nausea: pentoxifylline 22/151 (14.6%), control 12/146 (8.2%) (<LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-09-17 14:22:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>This review summarises the available randomised controlled trials of pentoxifylline or propentofylline in acute ischaemic stroke. A non-significant reduction in early case fatality was apparent for patients randomised to pentoxifylline or propentofylline although the confidence interval was wide reflecting the low numbers of patients studied such that these methylxanthines could equally reduce the odds of short-term case fatality by 59% or increase it by 2%.</P>
<P>One trial compared pentoxifylline and aspirin with aspirin alone and found a significant (P &lt; 0.002) 90% decrease in short-term mortality (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>); this same trial studied early death or deterioration and found this combined outcome to be non-significantly reduced. The Huber trial of 30 patients studied late case fatality (less than one year) following propentofylline treatment and found no difference between the treatment groups (<LINK REF="STD-Huber-1993" TYPE="STUDY">Huber 1993</LINK>).</P>
<P>Only one trial administered pentoxifylline within 12 hours (<LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>); the other trials delayed drug administration until later when ischaemic damage may be fixed and far less amenable to pharmacological intervention.</P>
<P>Two trials used stratification at the time of randomisation to prospectively assess the effect of drug intervention in sub-groups of patients. Chan and Kay stratified by cortical and lacunar infarction and analysed these subgroups separately. Whilst pentoxifylline appeared to offer no benefit to patients with lacunar infarcts, it significantly reduced (P &lt; 0.002) early (one week) case fatality in patients with cortical infarction (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>). This trial gave aspirin to both patient groups and it is possible that aspirin may potentiate the antiplatelet effects of pentoxifylline thereby contributing to its apparent clinical efficacy (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>). In contrast, the Hsu trial prospectively stratified patients by vascular territory (carotid versus vertebrobasilar); however, the subgroups did not differ in preliminary analysis and the results were published as a single group (<LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>). The Hsu trial found that patients with severe neurological deficits appeared to benefit most from pentoxifylline (<LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>); in contrast, Wong and colleagues found that pentoxifylline appeared to benefit milder patients (<LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>). The findings that different subgroups of patients benefited following treatment with pentoxifylline suggests that these were probably due to chance.</P>
<P>Three trials followed the intravenous pentoxifylline with oral pentoxifylline (<LINK REF="STD-Hoechst-1986" TYPE="STUDY">Hoechst 1986</LINK>; <LINK REF="STD-Hsu-1988" TYPE="STUDY">Hsu 1988</LINK>; <LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>). Hsu reported improved neurological deficit scores during the first three days of intravenous pentoxifylline but not during the subsequent oral treatment period between days four and 28 post-stroke; this difference was attributed to reduced pentoxifylline plasma levels during oral administration, as has been previously observed (<LINK REF="REF-Herskovits-1981" TYPE="REFERENCE">Herskovits 1981</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Existing randomised controlled trials of pentoxifylline and propentofylline suggest that they might reduce case fatality following acute ischaemic stroke. However, the number of trials and participants studied were too small and the trial designs were, in the main, suboptimal (particularly with respect to the delay in administering the drug) so that further research is required. Pentoxifylline or propentofylline should not currently be used in the routine management of acute ischaemic stroke.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The existing trial evidence, whilst based on a small number of patients, suggest that methylxanthines such as pentoxifylline and propentofylline might improve outcome. Hence, one or more larger trials of pentoxifylline or propentofylline are warranted in acute ischaemic stroke. Such a study might combine aspirin with the methylxanthine and stratify patients into cortical and lacunar infarction. Current evidence suggests that there is no benefit in giving oral pentoxifylline following its intravenous administration in view of the problems in maintaining adequate therapeutic levels of the drug.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-09-17 14:24:48 +0100" MODIFIED_BY="Hazel Fraser">
<P>We are grateful to Drs Chan (<LINK REF="STD-Chan-1993" TYPE="STUDY">Chan 1993</LINK>), Heiss (<LINK REF="STD-Huber-1993" TYPE="STUDY">Huber 1993</LINK>) and Wong (<LINK REF="STD-Wong-1987" TYPE="STUDY">Wong 1987</LINK>) for providing extra details on their trials. We are also grateful to Ms Brenda Malanka of the Ottawa Stroke Trials Registry for helping us to identify relevant trials, and to the Editorial Board of the Cochrane Stroke Group and external peer reviewer for making constructive comments on this review. We thank Kjell Asplund who interpreted the data and provided general advice in the first version of this review.</P>
<P>All the analyses and interpretations reflect our own work and opinions; Hoechst (the manufacturer of pentoxifylline) were not involved in the analyses or their interpretation.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-09-17 14:25:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-09-17 14:24:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>Philip Bath: conceived and designed the review; developed the search strategy; wrote and updated the review; and interpreted the data. He is the Guarantor for the review.</P>
<P>Fiona Bath-Hextall: co-ordinated the review; collected data; entered data; undertook searches; analysed the data; and wrote the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>NOTE: This review covers an area where no active research is taking place. It will be updated if relevant information becomes available, e.g. on completion of an appropriate study.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-17 14:44:31 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2008-09-17 14:44:31 +0100" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2008-09-17 14:38:45 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-1993" NAME="Chan 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chan YW, Kay CS</AU>
<TI>Pentoxifylline in the treatment of acute ischaemic stroke - a reappraisal in Chinese stroke patients</TI>
<SO>Clinical and Experimental Neurology</SO>
<YR>1993</YR>
<VL>30</VL>
<PG>110-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chan YW</AU>
<TI>Pentoxifylline in the treatment of acute ischaemic stroke - a reappraisal</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1991</YR>
<VL>21</VL>
<NO>4 suppl 2</NO>
<PG>601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Hoechst-1986" NAME="Hoechst 1986" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Aschenbrenner KM</AU>
<TI>Addendum to the final report. Efficacy, safety and tolerance of Trental (pentoxifylline) in the treatment of acute non-hemorrhagic focal cerebral infarction (12 - 36 hours after onset)</TI>
<SO>Hoechst AG (HRPI protocol 402 B - modified)</SO>
<YR>1987</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Hentschel B, Forthofer R</AU>
<TI>Efficacy, safety and tolerance of Trental (pentoxifylline) in the treatment of acute non-hemorrhagic focal cerebral infarction (12-36 hours after onset). Final report</TI>
<SO>Hoechst (HRPI protocol 402 B - modified)</SO>
<YR>1986</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hsu-1988" NAME="Hsu 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<TI>Clinical/statistical report for pentoxifylline (Trental, BL 191)</TI>
<SO>Hoechst (Protocol 402A)</SO>
<YR>1988</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hsu CY, Norris JW, Hogan EL, Bladin P, Dinsdale HB, Yatsu FM, et al</AU>
<TI>Pentoxifylline in acute nonhemorrhagic stroke. A randomised, placebo-controlled double-blind trial</TI>
<SO>Stroke</SO>
<YR>1988</YR>
<VL>19</VL>
<NO>6</NO>
<PG>716-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pentoxifylline Study Group</AU>
<TI>Pentoxifylline (PTX) in acute ischemic stroke</TI>
<SO>Stroke</SO>
<YR>1987</YR>
<VL>18</VL>
<NO>1</NO>
<PG>298</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huber-1993" NAME="Huber 1993" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Huber M, Hojer C, Fink G R, Neveling B, Kittner B, Heiss W D</AU>
<TI>Adenosine reuptake inhibition by propentofylline improves brain glucose metabolism as measured by FDG-PET in human acute ischemic stroke. A randomized, placebo-controlled, double-blind study</TI>
<SO>2nd International Conference on Stroke, Geneva</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huber M, Kittner B, Hojer C, Fink G R, Neveling M, Heiss W-D</AU>
<TI>Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke</TI>
<SO>Journal of Cerebral Blood Flow and Metabolism</SO>
<YR>1993</YR>
<VL>13</VL>
<PG>526-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wong-1987" MODIFIED="2008-09-17 14:38:45 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wong 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-09-17 14:38:45 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Wong WJ, Hu HH, Lo YK, Chu FL</AU>
<TI>A control trial of pentoxifylline plus glycerine in the treatment of acute ischemic stroke</TI>
<SO>Abstracts of the 7th Asian Oceanian Congress of Neurology, Bali</SO>
<YR>September 1987</YR>
<PG>45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong WJ, Hu HH, Lo YK, Luk YO, Chu FL</AU>
<TI>Treatment of acute ischemic stroke</TI>
<SO>Bulletin of the Neurological Society (Taiwan)</SO>
<YR>1987</YR>
<VL>12</VL>
<PG>20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-09-17 14:44:31 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Apollonio-1989" MODIFIED="2008-09-17 14:42:24 +0100" MODIFIED_BY="Hazel Fraser" NAME="Apollonio 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-09-17 14:42:24 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apollonio A, Castignani L, Magrini L, Angeletti R</AU>
<TI>Ticlopidine-pentoxifylline combination in the treatment of atherosclerosis and the prevention of cerebrovascular accidents</TI>
<SO>Journal of International Medical Research</SO>
<YR>1989</YR>
<VL>17</VL>
<PG>28-35</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:42:24 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beyreder-1981" MODIFIED="2008-09-17 14:42:32 +0100" MODIFIED_BY="Hazel Fraser" NAME="Beyreder 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-09-17 14:42:32 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beyreder J</AU>
<TI>Therapy of acute cerebrovascular insufficiency</TI>
<TO>Zur therapie der akuten zerebrovaskularen insuffizienz</TO>
<SO>Fortschritte der Therapie</SO>
<YR>1981</YR>
<VL>99</VL>
<NO>16</NO>
<PG>1-6</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:42:32 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beyreder J</AU>
<TI>Use of pentoxifylline in the treatment of acute cerebrovascular insufficiency</TI>
<SO>European Neurology</SO>
<YR>1983</YR>
<VL>22</VL>
<NO>Supp 1</NO>
<PG>116-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bowton-1989" MODIFIED="2008-09-17 14:42:42 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bowton 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-09-17 14:42:42 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bowton DL, Stump DA, Prough DS, Toole JF, Lefkowitz DS, Coker L</AU>
<TI>Pentoxifylline increases cerebral blood flow in patients with cerebrovascular disease</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<NO>12</NO>
<PG>1662-6</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:42:42 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1989" MODIFIED="2008-09-17 14:42:50 +0100" MODIFIED_BY="Hazel Fraser" NAME="Brown 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-09-17 14:42:50 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown MM</AU>
<TI>Effect of oxpentifylline on blood viscosity and cerebral blood flow in man</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1989</YR>
<VL>28</VL>
<PG>488-92</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:42:50 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diklic_x002d_Jeremic-1989" MODIFIED="2008-09-17 14:42:59 +0100" MODIFIED_BY="Hazel Fraser" NAME="Diklic-Jeremic 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-09-17 14:42:59 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diklic-Jeremic V, Zikic M</AU>
<TI>Effects of pentoxiphylline on cerebral oedema and blood brain barrier</TI>
<SO>New Trends in Clinical Neuropharmacology</SO>
<YR>1989</YR>
<VL>III</VL>
<NO>2</NO>
<PG>109 (abstract)</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:42:59 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartmann-1985" MODIFIED="2008-09-17 14:43:07 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hartmann 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-09-17 14:43:07 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hartmann A</AU>
<TI>Regional cerebral blood flow in acute cerebral infarction during hypervolemic hemodilution</TI>
<SO>Cerebral Vascular Disease 5: Proceedings of World Federation of Neurology 12th International Salzburg Conference 1984</SO>
<YR>1985</YR>
<PG>206-14</PG>
<ED>Meyer JS, Lechner H, Reivich M, Ott EO</ED>
<PB>Elsevier Science Publishers</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS MODIFIED="2008-09-17 14:43:07 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartmann-1986" MODIFIED="2008-09-17 14:43:37 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hartmann 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-09-17 14:43:15 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann A, Tsuda Y</AU>
<TI>A controlled study on the effect of pentoxifylline and an ergot alkaloid derivative on regional cerebral blood flow in patients with chronic cerebrovascular disease</TI>
<SO>Angiology</SO>
<YR>1988</YR>
<VL>39</VL>
<NO>5</NO>
<PG>449-57</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:43:15 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-17 14:43:37 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann A, Tsuda Y</AU>
<TI>A controlled study on the effect of pentoxifylline and of an ergot alkaloid derivative on regional cerebral blood flow in patients with cerebrovascular disease</TI>
<SO>Angiology</SO>
<YR>1986</YR>
<VL>37</VL>
<NO>5</NO>
<PG>399-400 (abstract)</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:43:37 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartmann-1991" MODIFIED="2008-09-17 14:43:50 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hartmann 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-09-17 14:43:50 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann A, Rommel T, Dettmers C, Tsuda Y, Lagreze H, Broich K</AU>
<TI>Hemodilution in cerebral infarcts</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1991</YR>
<VL>41</VL>
<NO>3a</NO>
<PG>348-51</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:43:50 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Hoechst-1985" MODIFIED="2008-09-17 14:39:27 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hoechst 1985" YEAR="1985">
<REFERENCE MODIFIED="2008-09-17 14:39:27 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="OTHER">
<AU>Hoechst</AU>
<TI>Etude multicentrique en double aveugle contre placebo dr l efficacite et de la tolerance du Torental par voie orale dans les infarctus sylviens a la phase aigue</TI>
<SO>Hoechst Internal Report</SO>
<YR>1985</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Hoechst-1993" MODIFIED="2008-09-17 14:39:31 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hoechst 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-09-17 14:39:31 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="OTHER">
<AU>Kittner B</AU>
<TI>Propentofylline acute stroke study (PASS). HWA 285/6/MN/301/ST</TI>
<SO>Hoechst Draft Study Protocol</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janaki-1980" MODIFIED="2008-09-17 14:39:35 +0100" MODIFIED_BY="Hazel Fraser" NAME="Janaki 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-09-17 14:39:35 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-09-17 14:39:35 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janaki S</AU>
<TI>Pentoxifylline in strokes: A clinical study</TI>
<SO>Journal of International Medical Research</SO>
<YR>1980</YR>
<VL>8</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magne-1981" MODIFIED="2008-09-17 14:44:05 +0100" MODIFIED_BY="Hazel Fraser" NAME="Magne 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-09-17 14:44:05 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magne C, Bricout H, Guimbretiere J</AU>
<TI>Blood filterability and stroke</TI>
<SO>Clinical Hemorheology</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>5/6</NO>
<PG>487 (abstract)</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:44:05 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozdemir-1998" MODIFIED="2008-09-17 14:44:11 +0100" MODIFIED_BY="Hazel Fraser" NAME="Ozdemir 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-09-17 14:44:11 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozdemir G, Gucuyener D, Yucel F, Uzuner N, Ozkan S</AU>
<TI>Can pentoxifylline (PTX) be effective for intracerebral hematoma (ICH) resolution? A different measurement technique</TI>
<SO>European Journal of Neurology</SO>
<YR>1998</YR>
<VL>5</VL>
<NO>3</NO>
<PG>S108 (abstract)</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:44:11 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sen-1977" MODIFIED="2008-09-17 14:44:19 +0100" MODIFIED_BY="Hazel Fraser" NAME="Sen 1977" YEAR="1977">
<REFERENCE MODIFIED="2008-09-17 14:44:19 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sen S, Chakravarty A</AU>
<TI>Clinical experience with pentoxifylline in occlusive cerebrovascular disorders</TI>
<SO>Angiology</SO>
<YR>1977</YR>
<VL>5</VL>
<PG>340-5</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:44:19 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaya-1988" MODIFIED="2008-09-17 14:44:31 +0100" MODIFIED_BY="Hazel Fraser" NAME="Vaya 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-09-17 14:44:25 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santos M-T, Valles J, Aznar J, Yaya R, Perez-Requejo J L</AU>
<TI>Effects of dipyridamole, pentoxifylline or pipyridamole plus pentoxifylline on platelet reactivity in patients with ischemic cerebrovascular insufficiency</TI>
<SO>Thrombosis Research</SO>
<YR>1993</YR>
<VL>72</VL>
<NO>3</NO>
<PG>219-29</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:44:25 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<REFERENCE MODIFIED="2008-09-17 14:44:31 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vaya A, Aznar J, Villa P, Valles J, Sanos MT, Martinez-Sales V</AU>
<TI>Erythrocyte filterability in patients with cerebrovascular insufficiency. Effect of pentoxifylline and dipyridamole. Preliminary results</TI>
<SO>Clinical Hemorheology</SO>
<YR>1988</YR>
<VL>8</VL>
<NO>5</NO>
<PG>773-8</PG>
<IDENTIFIERS MODIFIED="2008-09-17 14:44:31 +0100" MODIFIED_BY="Hazel Fraser"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zorzon-1987" MODIFIED="2008-09-17 14:39:52 +0100" MODIFIED_BY="Hazel Fraser" NAME="Zorzon 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-09-17 14:39:52 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-09-17 14:39:52 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zorzon M, Monti F, Luogo TP, Cazzato G</AU>
<TI>La ticlopidina e la pentosifillina nell'infarto cerebrale acuto</TI>
<SO>Giornale di Clinica Medica</SO>
<YR>LXVIII</YR>
<VL>11</VL>
<PG>569-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-17 14:41:37 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-17 14:41:37 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Andine-1990" NAME="Andine 1990" TYPE="JOURNAL_ARTICLE">
<AU>Andine P, Rudolphi KA, Fredholm BB, Hagberg H</AU>
<TI>Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 rat hippocampus during transient ischaemia</TI>
<SO>British Journal of Pharmacology</SO>
<YR>1990</YR>
<VL>100</VL>
<PG>814-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bath-1995" NAME="Bath 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bath PMW</AU>
<TI>Treating acute ischaemic stroke</TI>
<SO>British Medical Journal</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>139-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bluhm-1985" NAME="Bluhm 1985" TYPE="JOURNAL_ARTICLE">
<AU>Bluhm RE, Molnar J, Cohen MM</AU>
<TI>The effect of pentoxifylline on the energy metabolism of ischemic gerbil brain</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1985</YR>
<VL>8</VL>
<PG>280-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeLeo-1988" NAME="DeLeo 1988" TYPE="JOURNAL_ARTICLE">
<AU>DeLeo J, Schubert P, Kreutzberg GW</AU>
<TI>Protection against ischemic brain damage using propentofylline in gerbils</TI>
<SO>Stroke</SO>
<YR>1988</YR>
<VL>19</VL>
<PG>1535-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ganser-1974" NAME="Ganser 1974" TYPE="JOURNAL_ARTICLE">
<AU>Ganser V, Boksay I</AU>
<TI>Effect of pentoxifylline on cerebral edema in cats</TI>
<SO>Neurology</SO>
<YR>1974</YR>
<VL>24</VL>
<PG>487-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartmann-1977" NAME="Hartmann 1977" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann JF, Becker RA, Cohen MM</AU>
<TI>Effects of pentoxifylline on cerebral ultrastructure of normal and ischemic gerbils</TI>
<SO>Neurology</SO>
<YR>1977</YR>
<VL>27</VL>
<PG>77-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herskovits-1981" NAME="Herskovits 1981" TYPE="JOURNAL_ARTICLE">
<AU>Herskovits E, Vazquez A, Famulari A, et al</AU>
<TI>Randomized trial of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transient ischaemic attacks</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>i</VL>
<PG>966-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martindale-1993" NAME="Martindale 1993" TYPE="BOOK">
<AU>Reynolds JEF (ed)</AU>
<SO>Martindale, the extra pharmacopoeia</SO>
<YR>1993</YR>
<EN>30th</EN>
<PB>The Pharmaceutical Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miyashita-1992" NAME="Miyashita 1992" TYPE="JOURNAL_ARTICLE">
<AU>Miyashita K, Nakajima T, Ishikawa A, Miyatake T</AU>
<TI>An adenosine uptake blocker, propentofylline, reduces glutamate release in gerbil hippocampus following transient forebrain ischaemia</TI>
<SO>Neurochemical Research</SO>
<YR>1992</YR>
<VL>17</VL>
<PG>147-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ott-1983" NAME="Ott 1983" TYPE="JOURNAL_ARTICLE">
<AU>Ott E, Fazekas F, Lechner H</AU>
<TI>Haemorheological effects of pentoxifylline in disturbed blood flow behaviour in patients with cerebrovascular disease</TI>
<SO>European Neurology</SO>
<YR>1983</YR>
<VL>22</VL>
<NO>Suppl 1</NO>
<PG>105-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schneider-1983" NAME="Schneider 1983" TYPE="JOURNAL_ARTICLE">
<AU>Schneider R, Schmid-Schoenbein H, Kiesewetter H</AU>
<TI>The rheological efficiency of parenteral pentoxifylline (Trental) in patients with ischemic brain lesions</TI>
<SO>European Neurology</SO>
<YR>1983</YR>
<VL>22</VL>
<NO>Suppl 1</NO>
<PG>98-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vukadinovic-1986" NAME="Vukadinovic 1986" TYPE="JOURNAL_ARTICLE">
<AU>Vukadinovic V, Stefanovich V, Rakic L</AU>
<TI>Effect of propentofylline on the GABA system of a rat brain</TI>
<SO>Drug Development Research</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>87-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ward-1987" NAME="Ward 1987" TYPE="JOURNAL_ARTICLE">
<AU>Ward A, Clissold SP</AU>
<TI>Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy</TI>
<SO>Drugs</SO>
<YR>1987</YR>
<VL>34</VL>
<PG>50-97</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-09-17 14:47:58 +0100" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-09-17 14:47:24 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-09-17 14:27:09 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Chan-1993">
<CHAR_METHODS MODIFIED="2008-09-17 14:25:26 +0100" MODIFIED_BY="Hazel Fraser">
<P>Double-blind placebo-controlled<BR/>Single centre<BR/>Intention-to-treat<BR/>No loss to FU<BR/>Randomisation by sealed numbered opaque envelopes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-17 14:25:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>Hong Kong<BR/>Males 73, females 37<BR/>Mean age 68 years<BR/>Enrolment between 36 to 48 hours<BR/>100% CT<BR/>Stratified by cortical and lacunar infarction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-17 14:26:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: continuous intravenous PTX (Hoechst, China) 600 mg daily for 5 days with oral aspirin 150 mg daily<BR/>PL isotonic saline/matching PL injections with oral aspirin 150 mg daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-17 14:27:09 +0100" MODIFIED_BY="Hazel Fraser">
<P>Death at one week<BR/>Neurological impairment (modified Scandinavian Stroke Scale) at entry and 1 week</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-17 14:27:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ex: previous stroke, other neurological disease, TIA, cerebral haemorrhage, systemic disease<BR/>FU: 1 week</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-17 14:33:40 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Hoechst-1986">
<CHAR_METHODS MODIFIED="2008-09-17 14:26:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>Double-blind placebo-controlled<BR/>Multicentre (14 sites)<BR/>Intention-to-treat (efficacy data also available)<BR/>8 patients incompletely followed-up<BR/>Randomisation method not detailed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-17 14:26:56 +0100" MODIFIED_BY="Hazel Fraser">
<P>Austria, Belgium, Mexico, Sweden<BR/>153 male, 111 female, 2 unknown<BR/>Mean age 67 years<BR/>Enrolment between 12 to 36 hours<BR/>100% CT (optional scan at 7 days)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-17 14:33:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: PTX (Trental) loading with 50 mg iv then 16 mg/Kg/day (maximum daily dose 1200 mg) for 72 hours (or 7 days if dysphagia)<BR/>After infusion, 400 mg PTX po tds (or bd.) for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-17 14:27:59 +0100" MODIFIED_BY="Hazel Fraser">
<P>Case fatality at day 28<BR/>Neurological impairment (level of consciousness, motor, cranial nerve, higher cortical, and sensory function) on days 1, 2, 3, 4, 7, 14, 21, 28<BR/>Functional impairment (National Survey of Stroke) at days 4, 7, 14, 21, 28</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-17 14:28:07 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ex: recurrent stroke, intracranial haemorrhage, space-occupying lesion (tumour, vascular malformation), cranial trauma, multiple cerebral emboli if heart disease or TIA, severe chronic disease, drug hypersensitivity, anticoagulant therapy<BR/>FU: 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-17 14:47:15 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Hsu-1988">
<CHAR_METHODS MODIFIED="2008-09-17 14:28:19 +0100" MODIFIED_BY="Hazel Fraser">
<P>Double-blind, placebo-controlled<BR/>Multicentre (13 sites)<BR/>Intention to treat<BR/>No loss to FU<BR/>Randomisation by computer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-17 14:28:31 +0100" MODIFIED_BY="Hazel Fraser">
<P>USA, Canada, Australia<BR/>172 male, 125 female<BR/>Age &gt; 35 years, mean age 69 years<BR/>Enrolment within 12 hours<BR/>Stratified by carotid and vertebrobasilar territories<BR/>100% CT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-17 14:33:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: PTX iv loading 50 mg over 1 minute, then 16 mg/Kg/day (up to 1200 mg/day) for 72 hours (or 7 days if dysphagia) After infusion 400 mg PTX po tds for 25 days<BR/>PL: isotonic saline and matching tablets</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-17 14:47:15 +0100" MODIFIED_BY="Hazel Fraser">
<P>Death at 28 days<BR/>Neurological impairment (level of consciousness, motor, cranial nerve, higher cortical, and sensory functions) at baseline, days 1 to 4, 7, 14, 21, 28<BR/>Functional impairment (Barthel Index) at days 7, 14, 21, 28</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-17 14:28:55 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ex: pregnancy, previous stroke, TIA, coma, cerebral haemorrhage, systemic diseases, intracranial lesion other than stroke, anticoagulation<BR/>FU: 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-17 14:47:24 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Huber-1993">
<CHAR_METHODS MODIFIED="2008-09-17 14:29:04 +0100" MODIFIED_BY="Hazel Fraser">
<P>Double-blinded placebo controlled<BR/>Intention to treat<BR/>No loss to follow up<BR/>Randomisation by sealed numbered opaque envelopes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-17 14:29:13 +0100" MODIFIED_BY="Hazel Fraser">
<P>Germany<BR/>17 male, 10 female<BR/>Mean age 65 years<BR/>Enrolment &lt; 48 hrs<BR/>100% CT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-17 14:34:03 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: PPF (Hoechst) iv infusion 1200 mg within 72 hours of ictus for 7 days<BR/>PL: carrier solution<BR/>Both groups received 6% hydroxyethylstarch (500 ml/day iv for 14 days) and 10% glycerol iv for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-17 14:29:42 +0100" MODIFIED_BY="Hazel Fraser">
<P>Death at 2 weeks and 3 months<BR/>Neurological impairment (Mathews score) at admission and 2 weeks<BR/>Functional impairment (Barthel index) at 14 days and 3 months<BR/>FDG PET (rCMRglu) at admission and 14 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-17 14:47:24 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ex: Mathew score &gt; 65, subarachnoid haemorrhage, intracerebral haematoma, recent myocardial or cerebral infarction, cardiac arrhythmias, circulatory insufficiency, renal or hepatic failure, systemic infection, non-stabilised diabetes mellitus, coma<BR/>FU: 3 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-09-17 14:35:01 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Wong-1987">
<CHAR_METHODS MODIFIED="2008-09-17 14:30:03 +0100" MODIFIED_BY="Hazel Fraser">
<P>Single-blind (patients) placebo-controlled<BR/>Single centre<BR/>Intention to treat<BR/>No loss to follow up<BR/>Randomisation by identical numbered vials</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-09-17 14:30:33 +0100" MODIFIED_BY="Hazel Fraser">
<P>Taiwan<BR/>76 males, 14 females<BR/>Mean age not stated<BR/>Enrolment within 36 hours<BR/>100% CT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-09-17 14:30:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>Rx: PTX 900 mg/day iv and glycerine 1000 ml/day for 3 days, then 600-1200 mg/day po (length of oral therapy not stated)<BR/>Pl: glycerine 1000 ml/day iv</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-09-17 14:34:54 +0100" MODIFIED_BY="Hazel Fraser">
<P>Death at 28 days<BR/>Neurological impairment (Hoechst score, total score 100) and Barthel Index at 28 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-09-17 14:35:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ex: ICH, TIA, ventrebrobasilar stroke, recent MI, malignancy<BR/>FU: 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CI: cerebral infarction<BR/>Ex: exclusion criteria<BR/>FU: follow up<BR/>ICH: intracerebral haemorrhage<BR/>MI: myocardial infarction<BR/>PL: placebo<BR/>PPF: propentofylline<BR/>PTX: pentoxifylline<BR/>Rx: treatment<BR/>TIA: transient ischaemic attack</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-09-17 14:47:58 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-09-17 14:47:58 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Apollonio-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 14:47:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomised trial of combined PTX and ticlopidine versus combined aspirin, dipyridamole and buflomedil versus combined buflomedil and placebo in 79 patients with TIA or recent/chronic stroke. Assessment of functional outcome, recurrence and arterial blood flow direction (doppler). Excluded: (i) confounded with no control group; (ii) time from stroke unclear; (iii) no relevant outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 14:37:58 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Beyreder-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 14:37:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomised trial of PTX (n = 25) versus combined hexobendine, ethamivan and etofylline (n = 32) in 57 patients with acute (&lt; 24 hours) ischaemic stroke. Excluded: (i) confounded with no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 14:37:57 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Bowton-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 14:37:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomised dose comparison of PTX in 10 patients with chronic (&gt; 3 months) ischaemic stroke. Assessment of cerebral blood flow (xenon 133 clearance). Excluded: (i) non-acute study; (ii) no relevant outcomes; (iii) confounded with no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 14:37:55 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Brown-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 14:37:55 +0100" MODIFIED_BY="Hazel Fraser">
<P>Randomised trial of PTX versus control in 8 patients with chronic TIA or ischaemic stroke. Assessment of blood and plasma viscosity (viscometer) cerebral blood flow (xenon 133 clearance). Excluded: (i) non-acute study; (ii) no relevant outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Diklic_x002d_Jeremic-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of PTX versus control (n = 15) in 83 patients with recent (&lt; 27 days) cerebral infarction. Assessment of blood-brain barrier integrity (serum:CSf albumin). Excluded: (i) randomisation status unclear; (ii) no relevant outcomes; (iii) non-acute study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hartmann-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised comparison of PTX (n = 5) versus matched controls (n = 5) in 10 patients with acute (&lt; 36 hours) ischaemic stroke. Assessment of regional cerebral blood flow (xenon 133 clearance). Excluded: (i) not randomised; (ii) no relevant outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hartmann-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised trial of PTX versus codergocrine mesylate versus control in 90 patients with chronic cerebrovascular disease. Assessment of cerebral blood flow (xenon 133 clearance). Excluded: (i) non-acute study; (ii) no relevant outcomes; most patients non-stroke (multi-infarct dementia).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hartmann-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised trial of single 4 hour infusions of PTX (n = 10) versus dextran (n = 10) versus hydroxyethyl starch (n = 10) versus glucose (n = 10) in 40 patients with acute (&lt; 24 hours) anterior circulation ischaemic stroke. Assessment of CBF (xenon 133 clearance). Excluded: (i) No relevant outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoechst-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Internal company report unavailable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoechst-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Proposed multinational multicentre phase III trial of PPF (1200 mg/day iv for 3 to 14 days then 300 mg tds po for 3 months) within 12 hours of acute ischaemic stroke. Trial cancelled by Hoechst; 0 of 1600 patients enrolled. Excluded: (i) trial aborted prior to recruitment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Janaki-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised trial of PTX (n = 29) versus xanthinol nicotinate (n = 29) in 58 patients with recent (&lt; 14 days) cerebral thrombosis. Assessment of motor impairment, cognition, memory and speech. Assessment of functional outcome. Excluded: (i) confounded with no control group; (ii) non-acute study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Magne-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised trial of PTX (n = 13) versus placebo (n = 9) in 22 patients with arterial brain infarct. Assessment of whole blood filterability. Excluded: (i) no relevant outcomes; (ii) time since stroke uncertain.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ozdemir-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Controlled trial of PTX (n = 10) versus control (n = 10) in 20 patients with acute primary intracerebral haemorrhage (without ventricular haematoma). Assessment of haematoma size (CT scan) and functional outcome. Excluded: (i) haemorrhagic, not ischaemic stroke.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sen-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised trial of PTX (n = 28) versus xanthinol nicotinate (n = 24) in 52 patients with recent (&lt; 15 days) TIA or probable ischaemic stroke. Assessment of motor impairment and speech. Excluded: (i) confounded with no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 14:46:10 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Vaya-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 14:46:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>Pseudo-randomised trial comparing PTX (n = 9) versus dipyridamole (n = 6) versus combined PTX and dipyridamole (n = 6) in 21 patients with chronic (6 to 8 months) ischaemic stroke (and 36 control participants). Assessment of filterability and platelet function (aggregation). Excluded: (i) non-acute study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zorzon-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised trial of PTX versus ticlopidine. Excluded: (i) no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>PPF: propentofylline<BR/>PTX: pentoxifylline/oxpentifylline</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Chan-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hoechst-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hsu-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Huber-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wong-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Pentoxifylline or analogue versus control in ischaemic stroke: all trials</NAME>
<DICH_OUTCOME CHI2="8.39407970075589" CI_END="1.0188639018611363" CI_START="0.4072833390529057" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6441787733156655" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="49" I2="52.34736692290641" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.008116175548904076" LOG_CI_START="-0.390103355456312" LOG_EFFECT_SIZE="-0.19099358995370394" METHOD="PETO" NO="1" P_CHI2="0.07816375118205332" P_Q="0.8138980026547711" P_Z="0.06009835999171944" Q="0.055413333044016966" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="408" TOTAL_2="385" WEIGHT="100.0" Z="1.8800713096232724">
<NAME>Case fatality, early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.338666367711873" CI_END="1.0394385775994945" CI_START="0.4080812670011654" DF="3.0" EFFECT_SIZE="0.6512875031172416" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="47" I2="64.02302397399791" ID="CMP-001.01.01" LOG_CI_END="0.016798831139599995" LOG_CI_START="-0.3892533410874348" LOG_EFFECT_SIZE="-0.18622725497391737" NO="1" P_CHI2="0.03950728985519025" P_Z="0.07220994491292715" STUDIES="4" TAU2="0.0" TOTAL_1="393" TOTAL_2="370" WEIGHT="96.17926121702953" Z="1.7977921934847088">
<NAME>Pentoxifylline</NAME>
<DICH_DATA CI_END="1.458077948228481" CI_START="0.38610541928484915" EFFECT_SIZE="0.7503144657746845" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.1637807418013094" LOG_CI_START="-0.4132941026779744" LOG_EFFECT_SIZE="-0.12475668043833248" ORDER="1" O_E="-2.5" SE="0.3389766202136816" STUDY_ID="STD-Hoechst-1986" TOTAL_1="133" TOTAL_2="133" VAR="8.702830188679245" WEIGHT="47.61906093240974"/>
<DICH_DATA CI_END="5.194243749259129" CI_START="0.0019056432630093168" EFFECT_SIZE="0.09949058049485845" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7155223258235799" LOG_CI_START="-2.7199583961462803" LOG_EFFECT_SIZE="-1.0022180351613503" ORDER="2" O_E="-0.5666666666666667" SE="2.0180183819889375" STUDY_ID="STD-Wong-1987" TOTAL_1="51" TOTAL_2="39" VAR="0.24555555555555555" WEIGHT="1.343600266669835"/>
<DICH_DATA CI_END="2.046869450370228" CI_START="0.453397139496891" EFFECT_SIZE="0.9633507947375322" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.311090144180895" LOG_CI_START="-0.3435212241844343" LOG_EFFECT_SIZE="-0.016215540001769644" ORDER="3" O_E="-0.2525252525252526" SE="0.384521958156328" STUDY_ID="STD-Hsu-1988" TOTAL_1="151" TOTAL_2="146" VAR="6.763285323891385" WEIGHT="37.00650121389222"/>
<DICH_DATA CI_END="0.4379056678736896" CI_START="0.024838401475875675" EFFECT_SIZE="0.10429226619077836" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.358619433637887" LOG_CI_START="-1.6048763574707061" LOG_EFFECT_SIZE="-0.9817478955542966" ORDER="4" O_E="-4.218181818181818" SE="0.7320574861306645" STUDY_ID="STD-Chan-1993" TOTAL_1="58" TOTAL_2="52" VAR="1.8659913564333914" WEIGHT="10.21009880405774"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.101047785644177" CI_START="0.04681532219902458" DF="0.0" EFFECT_SIZE="0.4886790313053682" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.7076593919382393" LOG_CI_START="-1.3296119833058593" LOG_EFFECT_SIZE="-0.3109762956838099" NO="2" P_CHI2="1.0" P_Z="0.5496053262803492" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.8207387829704698" Z="0.5983516452371671">
<NAME>Propentofylline</NAME>
<DICH_DATA CI_END="5.101047785644177" CI_START="0.04681532219902458" EFFECT_SIZE="0.4886790313053682" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7076593919382393" LOG_CI_START="-1.3296119833058593" LOG_EFFECT_SIZE="-0.3109762956838099" ORDER="112800" O_E="-0.5" SE="1.1967032904743342" STUDY_ID="STD-Huber-1993" TOTAL_1="15" TOTAL_2="15" VAR="0.6982758620689655" WEIGHT="3.8207387829704698"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6818300186688333" CI_START="0.1321382163485808" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6975030118684518" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.5660637342879802" LOG_CI_START="-0.878971559758646" LOG_EFFECT_SIZE="-0.156453912735333" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6712665076357113" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.42441044238152825">
<NAME>Case fatality, late</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Pentoxifylline</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.6818300186688333" CI_START="0.1321382163485808" DF="0.0" EFFECT_SIZE="0.6975030118684518" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.5660637342879802" LOG_CI_START="-0.878971559758646" LOG_EFFECT_SIZE="-0.156453912735333" NO="2" P_CHI2="1.0" P_Z="0.6712665076357113" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="0.42441044238152825">
<NAME>Propentofylline</NAME>
<DICH_DATA CI_END="3.6818300186688333" CI_START="0.1321382163485808" EFFECT_SIZE="0.6975030118684518" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5660637342879802" LOG_CI_START="-0.878971559758646" LOG_EFFECT_SIZE="-0.156453912735333" ORDER="112801" O_E="-0.5" SE="0.8488208847630565" STUDY_ID="STD-Huber-1993" TOTAL_1="15" TOTAL_2="15" VAR="1.3879310344827585" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04629377333849799" CI_END="1.2006561655964405" CI_START="0.19661560951514973" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.48586803127687533" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.07941865539339389" LOG_CI_START="-0.7063820060502377" LOG_EFFECT_SIZE="-0.3134816753284219" METHOD="PETO" NO="3" P_CHI2="0.8296428299189604" P_Q="1.0" P_Z="0.11786738061407974" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="91" WEIGHT="100.0" Z="1.5637879263889103">
<NAME>Death or disability, early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.04629377333849799" CI_END="1.2006561655964405" CI_START="0.19661560951514973" DF="1.0" EFFECT_SIZE="0.48586803127687533" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.07941865539339389" LOG_CI_START="-0.7063820060502377" LOG_EFFECT_SIZE="-0.3134816753284219" NO="1" P_CHI2="0.8296428299189604" P_Z="0.11786738061407974" STUDIES="2" TAU2="0.0" TOTAL_1="109" TOTAL_2="91" WEIGHT="100.0" Z="1.5637879263889103">
<NAME>Pentoxifylline</NAME>
<DICH_DATA CI_END="1.8398428741320114" CI_START="0.09985565527290886" EFFECT_SIZE="0.4286242127967621" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2647807350686611" LOG_CI_START="-1.0006273340554919" LOG_EFFECT_SIZE="-0.3679232994934154" ORDER="1" O_E="-1.5333333333333332" SE="0.743306963674492" STUDY_ID="STD-Wong-1987" TOTAL_1="51" TOTAL_2="39" VAR="1.8099375780274656" WEIGHT="38.56235790519312"/>
<DICH_DATA CI_END="1.6670626073773218" CI_START="0.16573991845981845" EFFECT_SIZE="0.5256413421850774" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.22195191028266825" LOG_CI_START="-0.780572879155041" LOG_EFFECT_SIZE="-0.2793104844361864" ORDER="2" O_E="-1.8545454545454545" SE="0.5888880238934536" STUDY_ID="STD-Chan-1993" TOTAL_1="58" TOTAL_2="52" VAR="2.8835969368413075" WEIGHT="61.43764209480689"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Propentofylline</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>